Colorectal Cancer Control: Where Have We Been and Where Should We Go Next?

doi:10.1001/jamainternmed.2018.4627

Comment

. 2018 Dec 1;178(12):1658-1660.

doi: 10.1001/jamainternmed.2018.4627.

Colorectal Cancer Control: Where Have We Been and Where Should We Go Next?

Beverly B Green¹

Affiliations

PMID: 30326022
PMCID: PMC6733580
DOI: 10.1001/jamainternmed.2018.4627

Comment

Colorectal Cancer Control: Where Have We Been and Where Should We Go Next?

Beverly B Green. JAMA Intern Med. 2018.

. 2018 Dec 1;178(12):1658-1660.

doi: 10.1001/jamainternmed.2018.4627.

Author

Beverly B Green¹

Affiliation

¹ Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle.

PMID: 30326022
PMCID: PMC6733580
DOI: 10.1001/jamainternmed.2018.4627

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment on

Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis.
Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, Cubillos L, Malo T, Reuland DS. Dougherty MK, et al. JAMA Intern Med. 2018 Dec 1;178(12):1645-1658. doi: 10.1001/jamainternmed.2018.4637. JAMA Intern Med. 2018. PMID: 30326005 Free PMC article.

Cited by

Increasing Fecal Immunochemical Test Return Rates by Implementing Effective "Reminder to Complete Kit" Communication With Participants: A Quality Improvement Study.
Prakash S, Merza N, Hosseini O, Ward H, Mansi T, Balducci M, Trammell D, Hernandez B, Obokhare I. Prakash S, et al. Cureus. 2022 May 20;14(5):e25169. doi: 10.7759/cureus.25169. eCollection 2022 May. Cureus. 2022. PMID: 35746986 Free PMC article.
Gastroenterology visitation and reminders predict surveillance uptake for patients with adenomas with high-risk features.
Myint A, Corona E, Yang L, Nguyen BS, Lin C, Huang MZ, Shao P, Mwengela D, Didero M, Asokan I, Bui AAT, Hsu W, Maehara C, Naini BV, Kang Y, Bastani R, May FP. Myint A, et al. Sci Rep. 2021 Apr 22;11(1):8764. doi: 10.1038/s41598-021-88376-4. Sci Rep. 2021. PMID: 33888839 Free PMC article.
A Patient Portal-Based Commitment Device to Improve Adherence with Screening for Colorectal Cancer: a Retrospective Observational Study.
Hahn EE, Baecker A, Shen E, Haupt EC, Wakach W, Ahuja A, Imley TM, Gould MK, Kanter M. Hahn EE, et al. J Gen Intern Med. 2021 Apr;36(4):952-960. doi: 10.1007/s11606-020-06392-y. Epub 2021 Jan 20. J Gen Intern Med. 2021. PMID: 33474640 Free PMC article.
Outreach and Inreach Strategies for Colorectal Cancer Screening Among Latinos at a Federally Qualified Health Center: A Randomized Controlled Trial, 2015-2018.
Castañeda SF, Bharti B, Rojas M, Mercado S, Bearse AM, Camacho J, Lopez MS, Muñoz F, O'Connell S, Liu L, Talavera GA, Gupta S. Castañeda SF, et al. Am J Public Health. 2020 Apr;110(4):587-594. doi: 10.2105/AJPH.2019.305524. Epub 2020 Feb 20. Am J Public Health. 2020. PMID: 32078353 Free PMC article. Clinical Trial.

References

1. White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5014–5036. - PMC - PubMed
1. White A, Thompson TD, White MC, et al. Cancer screeningtest use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):201–206. doi:10.15585/mmwr.mm6608a1 - DOI - PMC - PubMed
1. Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Canc Netw. 2018;16(4):402–410. doi:10.6004/jnccn.2017.7065 - DOI - PubMed
1. Zheng Z, Yabroff KR, Guy GP Jr, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2015;108(5):108. - PMC - PubMed
1. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101(20):1412–1422. doi:10.1093/jnci/djp319 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

R01 CA121125/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5014–5036. - PMC - PubMed

[2] White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5014–5036. - PMC - PubMed

[3] White A, Thompson TD, White MC, et al. Cancer screeningtest use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):201–206. doi:10.15585/mmwr.mm6608a1 - DOI - PMC - PubMed

[4] White A, Thompson TD, White MC, et al. Cancer screeningtest use—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):201–206. doi:10.15585/mmwr.mm6608a1 - DOI - PMC - PubMed

[5] Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Canc Netw. 2018;16(4):402–410. doi:10.6004/jnccn.2017.7065 - DOI - PubMed

[6] Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Canc Netw. 2018;16(4):402–410. doi:10.6004/jnccn.2017.7065 - DOI - PubMed

[7] Zheng Z, Yabroff KR, Guy GP Jr, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2015;108(5):108. - PMC - PubMed

[8] Zheng Z, Yabroff KR, Guy GP Jr, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2015;108(5):108. - PMC - PubMed

[9] Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101(20):1412–1422. doi:10.1093/jnci/djp319 - DOI - PMC - PubMed

[10] Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009;101(20):1412–1422. doi:10.1093/jnci/djp319 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Colorectal Cancer Control: Where Have We Been and Where Should We Go Next?

Affiliation

Colorectal Cancer Control: Where Have We Been and Where Should We Go Next?

Author

Affiliation

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical